A study of pazopanib safety and efficacy in patients with advanced clear cell renal cell carcinoma and ECOG performance status 2 (Pazo2): an 0pen label, multicentre, single arm, phase II trial.
Zarkar, Anjali Pirrie, Sarah Stubbs, Clive Hodgkins, Anne-Marie Farrugia, David Fife, Kathryn MacDonald-Smith, Carey Vasudev, Naveen Porfiri, Emilio
Zarkar, Anjali
Pirrie, Sarah
Stubbs, Clive
Hodgkins, Anne-Marie
Farrugia, David
Fife, Kathryn
MacDonald-Smith, Carey
Vasudev, Naveen
Porfiri, Emilio
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-06-14
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Aim: Patients with advanced renal cell carcinoma and poor performance status (PS≥2) are often deemed unsuitable for treatment. The Pazo2 trial aimed to assess tolerability and efficacy of pazopanib as first-line treatment in renal cancer patients with ECOG PS2.
Methods: Pazo2 was a prospective, single arm, open label, multicentre, phase II trial, conducted in 26 UK centres. Eligible patients were aged ≥18 years, with advanced or metastatic renal cancer and a clear cell component (aRCC), measurable disease as per RECIST Criteria 1.1, and ECOG PS2. Co-primary outcomes, assessed at 6-months after patients entered the trial, were tolerability, defined as the proportion of patients who did not develop "intolerable" adverse events, and efficacy, defined as the proportion of all patients who were progression-free and alive.
Results: Between February 21, 2013 and August 12, 2016, 75 patients were registered. Median age was 68.6 years (IQR 64.6-76.0), 100% ECOG PS2, 62.7% 'poor risk' (International Metastatic Renal-Cell Carcinoma Database Consortium). Of the 65 evaluable patients, 70.8% (95% CI: 58.8, 80.4) did not develop "intolerable" adverse events and 56.9% (95% CI: 44.8, 68.2) were still alive and progression-free 6 months after starting pazopanib. Twenty-seven patients developed serious adverse events deemed to be related to pazopanib.
Conclusion: These data suggests that pazopanib is tolerated and effective in aRCC patients with PS2 and represents a treatment option for patients who cannot receive or tolerate immune checkpoint inhibitors.
Citation
Zarkar A, Pirrie S, Stubbs C, Hodgkins AM, Farrugia D, Fife K, MacDonald-Smith C, Vasudev N, Porfiri E; Pazo2 Investigators. A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial. Clin Genitourin Cancer. 2022 Oct;20(5):473-481. doi: 10.1016/j.clgc.2022.06.012. Epub 2022 Jun 14.
Type
Article